Directory of Stock Market Company
This site is a directory of Stock Market Company in USA and Canada. Each company page contains a description, stock quote, news and much more. You have also access to the best stock market game on the web.
Search into NYSE and TSX
by quote, company name or key word
ARQL - Arqule Inc
ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company’s product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy a","NYSE, Nasdaq, S&P, trading, US market, Asian market, Dow Jones, FTSE, DJIA, DAX, stocks, bonds, shares","Connect to the most current information on stocks and bonds on Reuters.com. What you need to know now about NYSE, Dow Jones, S&P, and Nasdaq at Reuters.com"
Arqule Inc News
Boston Monday Stock Wrap
Citybizlist (press release) - 20 hours ago
Citybizlist (press release) - 20 hours ago
Major Boston stocks rose with the market, closing up 2%. At Monday's close, the Dow Jones Industrial Average finished up 1.2%, the NASDAQ up 2.8%, and the S&P 500 up 1.7%.
Perrigo Announces FDA Final Approval and Launch of OTC Lansoprazole; Watson ...
BioMedReports (subscription) - May 19, 2012
BioMedReports (subscription) - May 19, 2012
By Staff and Wire Reports Below is a look at some of the headlines for companies that made news in the healthcare sector on May 18, 2012.
ArQule ready for Phase 3 lung cancer trial
Mass High Tech - May 18, 2012
Daiichi Sankyo, ArQule complete enrollment in tivantinib plus erlotinib Phase ... - News-Medical.net
Mass High Tech - May 18, 2012
By Don Seiffert ArQule Inc. (Nasdaq: ARQL) of Woburn and its partner, Tokyo-base Daiichi Sankyo Co. Ltd., have completed enrollment for a Phase 3 trial of ArQule's lead drug candidate to treat patients with locally-advanced or metastatic, non-squamous, ...
ArQule and Daiichi Sankyo Announce Completion of Patient Recruitment in Phase ... - EON: Enhanced Online News (press release)Daiichi Sankyo, ArQule complete enrollment in tivantinib plus erlotinib Phase ... - News-Medical.net
An Early Look at 2012 ASCO Biotech Cancer Stocks (DNDN, LLY, AMGN, ARIA, ARQL ...
24/7 Wall St. - May 18, 2012
24/7 Wall St. - May 18, 2012
Real-time Company News, Economic Reports, Analyst Calls, Upgrades, Downgrades, Initiations and Key Industry News as it happens. We are now just about two weeks away from the king of biotech and pharma events in cancer treatments.
ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) - TheStreet.com
ARQULE, INC. : ArQule and Daiichi Sankyo Announce Completion of Patient ...
4-traders - May 18, 2012
4-traders - May 18, 2012
ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo, Co., Ltd. (TSE 4568) today announced that recruitment of patients has been completed in the randomized, double-blind, controlled Phase 3 MARQUEE pivotal trial of their investigational selective c-MET ...
ASCO '12 Abstract Dump: Cancer Stocks in Focus - TheStreet.com
ASCO 2012 Abstracts: 4 Hopeful Overachievers
Seeking Alpha - May 18, 2012
Seeking Alpha - May 18, 2012
With ASCO 2012 rapidly approaching, investors have been hedging their bets on upcoming data via the many posters presented at the prestigious event.
Ariad Pharmaceuticals, ArQule, Exelixis, Aveo, Other Cancer Drug Stocks Fall
Minyanville.com - May 18, 2012
Minyanville.com - May 18, 2012
By Brett Chase May 17, 2012 20:00 pm Stocks for a number of cancer drug developers are falling Thursday as investors sift through scientific papers released ahead of a major medical conference next month.
Boston Scientific Announces FDA Approval of Stem Cell Drug; Osiris Receives ...
BioMedReports (subscription) - May 18, 2012
BioMedReports (subscription) - May 18, 2012
By Staff and Wire Reports Below is a look at some of the headlines for companies that made news in the healthcare sector on May 17, 2012.
Boston Wednesday Stock Wrap
Citybizlist (press release) - May 17, 2012
Citybizlist (press release) - May 17, 2012
Boston's notable stocks closed down 0.8% on a quiet day for the market. When the market closed on Wednesday, the Dow Jones Industrial Average finished down 0.1%, the NASDAQ down 0.7%, and the S&P 500 down 0.4%.
Positive Phase 2 Clinical Data With Tivantinib In Hepatocellular Carcinoma To ...
TheStreet.com (press release) - May 17, 2012
TheStreet.com (press release) - May 17, 2012
By Business Wire 05/17/12 - 07:30 AM EDT ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo, Co., Ltd. (TSE 4568) today announced that an oral presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) will feature Phase 2 trial ...
NYSE Media Coverage Selection of the best articles found in your favorit medias